hotspot -WSS

hotspot

author：leisure time 2025-09-08 19:56:57 - browse：1938

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： UnitedHealth CEO's Medicaid comments send insurer stocks diving

WSS

Structure Therapeutics oral GLP

Medicare Advantage's lean provider networks lead CMS complaints

Boston's new lab space is opening empty

Fight over Supreme Court dialysis ruling puts kidney patients at risk

Senators tussle over abortion against the backdrop of a presidential campaign

ASCO Daily Recap: CAR

knowledge

hotspot

knowledge

Peter Hotez and the public health issue of online harassment

How CO2 helps viruses stay alive longer in the air

ChatGPT in medicine: STAT answers readers' burning questions

Data don't support strong claims for Covid

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

The most pressing bird flu mysteries scientists want answered

At least 13 dead in Texas as scorching temps continue

Why depression after traumatic brain injury is distinct

Walensky prepares to leave CDC — and Congress — behind

Readout Newsletter: Bristol, Sangamo, Gilead, and more

focus

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

President Biden's budget: Here's what you might have missed

FDA approves Moderna’s RSV vaccine, its second licensed product

FDA approves Moderna’s RSV vaccine, its second licensed product

FTC loses bid to block Novant's North Carolina hospital merger

Readout Newsletter: CAR

focus

entertainment

explore

focus